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Background: We aimed to assess functional and radiological outcomes after bridging therapy (intravenous 
thrombolysis plus mechanical thrombectomy, MT) vs direct MT in unknown onset stroke patients. 
Methods: We conducted a cohort study on prospectively collected data from unknown onset stroke 
patients who received endovascular procedures ≤6 hours from symptom recognition or awakening time. 
Results: Of the 349 patients with 10-Point ASPECTS, 248 received bridging and 101 received direct MT. Of 
the 134 patients with 6-9-Point ASPECTS, 123 received bridging and 111 received direct MT. Each patient 
treated with bridging was propensity score matched with a patient treated with direct MT for age, sex, 
study period, pre-stroke disability, stroke severity, type of stroke onset, symptom recognition (or 
awakening)-to-groin time, ASPECTS, and procedure time. In the two matched groups with 10-Point ASPECTS 
(n=73 vs n=73), bridging was associated with higher rates of excellent outcome (46.6% vs 28.8%; OR: 2.302, 
95% CI: 1.010-5.244) and 
successful recanalization (83.6% vs 63%; OR: 3.028, 95% CI: 1.369-6.693) compared with  direct MT; no 
significant association were found between bridging and direct MT as regards rate of sICH (0 vs 1.4%). In 
the two matched groups with 6-9-Point ASPECTS (n=45 vs n=45), no significant associations were found 
between bridging and direct MT as regards rates of excellent functional outcome (44.4% vs 31.1%), 
successful recanalization (73.3% vs 76.5%), and sICH  (0 
vs 0). 
  
Conclusions: Bridging ≤6 hours of symptom recognition or awakening time was associated with better 










Mechanical thrombectomy (MT) has revolutionized care for ischemic stroke patients with intracranial 
internal carotid artery (ICA) or M1-segment middle cerebral artery (MCA) occlusion and Alberta Stroke 
Program Early CT Score (ASPECTS) ≥6.1 Bridging therapy (intravenous thrombolysis, IVT with Alteplase 
within 4.5 hours of known symptom onset plus MT) is recommended within 6 hours of known symptom 
onset,2 while direct MT is recommended in patients with contraindications for IVT.2,3 
DEFUSE-3 and DAWN trials provided evidence for effectiveness of direct MT between 6 hours and 
respectively 16 and 24 hours after the time the patient was last known to be well, according to strict 
selection criteria based on perfusion imaging and mismatch between clinical severity and infarct size.4,5 
WAKE-UP trial provided evidence for effectiveness of IVT in patients with unknown onset stroke and 
DWI/FLAIR-MRI mismatch,6 while EXTEND trial  provided  evidence for effectiveness of IVT between 4.5 
and 9 hours after known stroke onset or  awakening in patients with salvageable penumbra based on 
PWI/CBF-CT or PWI/DWI-MRI and infarct core volume.7 
Intracranial ICA, M1-MCA, or M2-MCA occlusion was reported in one third of patients enrolled in the 
WAKE-UP trial6 and in more than two thirds of patients enrolled in the EXTEND trial7,  but no patient 
received bridging therapy. At this point, some issues should be addressed. First, there are no  data from  
the trials  about  possible  differences  in  effectiveness  between bridging 
therapy and direct MT in patients with wake-up or unwitnessed stroke. Second, clinical and radiological 
criteria do not overlap across the trials for IVT alone and direct MT. Third, radiological selection according 
to trial protocols was based on the use of an automated software, 
  
which is not currently available everywhere, especially in the smaller community and rural hospitals. 
Non-contrast CT is available in all hospitals and is considered the reference standard for patients with 
suspected acute ischemic stroke who are candidates for IVT to exclude an acute intracranial hemorrhage 
and to detect early signs of ischemia in the MCA territory. Presence of  early ischemic changes on CT scan 
within 6-10-Point ASPECTS is listed in the current guidelines as a 
criterion for providing a strong recommendation in favor of bridging therapy ≤6 hours of known symptom 
onset.2 However, if the risk of sICH can be increased in patients with early ischemic changes on CT scan 
remains a controversial topic even within conventional time window for IVT.8 A recent clinical series 
reflecting routine practice reported that patients with wake-up  stroke and normal brain CT scan (10-Point 
ASPECTS) treated with IVT alone ≤4.5 hours from awakening time had similar safety and efficacy outcomes 
to stroke patients with known onset stroke.9 Instead, to the best of our knowledge, no data are available as 
regards safety and efficacy of bridging therapy in stroke patients with unknown symptom onset and normal 
CT scan. 
AIMS 
The aim of this study was to assess functional and radiological outcomes after bridging therapy (vs direct 
MT) in unknown onset stroke patients with 10-Point and 6-9-Point ASPECTS. 
  
METHODS 
Study design, participants, and procedures. We conducted a cohort study on prospectively collected data of 
patients enrolled in the Italian Registry of Endovascular Treatment in Acute Stroke (IRETAS) between 
January 2011 and December 2017 for acute ischemic stroke with intra-cranial ICA, M1-MCA, or M2-MCA 
occlusion and ASPECTS ≥6. The IRETAS is a multicenter, observational internet-based registry (Supplement 
Table 1). Participating centers were required to accept the rules of the IRETAS, including consecutive 
registration of all stroke patients receiving endovascular procedures irrespective of whether treatment was 
according to guidelines. 
We included unknown onset stroke patients without absolute exclusion criteria for IVT according to the 
Italian Stroke Organisation (ISO)-SPREAD guidelines,3 who received bridging therapy or direct MT ≤6 hours 
of symptom recognition (for unwitnessed stroke) or awakening time (for wake-up stroke). Similar to the 
time for treatment used by Armona et al.,9 patients treated with bridging therapy were included if they 
received IVT ≤4.5 hours of symptom recognition or awakening time. Patients treated with additional intra-
arterial fibrinolysis were excluded. 
Recruitment largely preceded the evidence for MT in unknown onset strokes,4-7  and the choice of 
type of endovascular procedure was at the discretion of the neurologist and neuroradiologist. Measures of 
salvageable penumbra based on PWI/CBF-CT or PWI/DWI-MRI and infarct core volume were not collected. 
Selection of patients for the present study was exclusively according to presence of early ischemic changes 
in CT scan within the range for which  the recommendations  are strong in  favor of endovascular treatment 
≤6  hours of known     symptom 
onset (6-10-Point ASPECTS):2  We divided the entire cohort into two group of patients:  10-Point 
ASPECTS group (i.e., normal CT scan) and 6-9-Point ASPECTS group. 
Data collection. Data collection is provided in the Supplementary Material. 
Outcome. Functional outcome measures were: a) excellent functional outcome, defined as mRS score 0-1), 
b) favorable functional outcome, defined as mRS score 0-2, and c) death at 3 months. Radiological outcome 
measures: a) complete recanalization, defined as thrombolysis in cerebral infarction (TICI) grading system 3 
and b) successful recanalization, defined as TICI grading system 2b/3, at the end of procedure; c) any type 
of ICH (hemorrhagic infarction, parenchymal hematoma  [PH],  or  subarachnoid   hemorrhage),  d)  PH,  
and   e)   symptomatic   intracerebral 
  
hemorrhage, defined as PH with increase of ≥4 NIHSS score points from baseline or death  within 24 hours. 
Statistical analysis. We performed statistical analyses using SPSS 22.0 statistical package. Normally 
distributed continuous variables were presented as means and standard deviation (SD) and were compared 
using Student’s t-tests. Not normally distributed continuous variables were presented as median and 
interquatile range (IQR) and were compared using Mann-Whitney U- test. Categorical variables were 
expressed as frequency and percentage and were compared using χ2 test. Proportions were calculated for 
categorical variables, dividing the number of events by the total number excluding missing/unknown cases. 
Endovascular treatment was not randomly assigned in the study population, so to reduce the risk of bias 
because of confounding, three models of propensity score matching was used for both 10- Point ASPECT 
and 6-9-Point ASPECTS groups. Using logistic regression, the first model of propensity score was calculated 
for each patient based on age, sex, study period, pre-stroke mRS score ≤1, NIHSS score, type of stroke 
onset, symptom recognition (or awakening)-to-groin puncture time, and procedure time. ASPECT score 
entered only the models for 6-9-Point ASPECTS group. The second model of propensity score was 
calculated for each patient based on covariates of the first model plus medical history (hypertension, 
diabetes mellitus, previous stroke/TIA, atrial fibrillation, antiplatelet, and anticoagulant), occlusion site, and 
general anesthesia. Among the covariates with large amounts of missing values (i.e., execution/or not of 
perfusion CT or MRI, Careggi collateral score, and type of procedure), the availability (or not) of advanced 
imaging is of utmost importance for choice of treatment and for predicting outcome; therefore, the third 
model of propensity score was calculated for each patient based on covariates of the second model plus 
execution (or not) of perfusion CT or MRI. Each patient treated with bridging therapy was propensity score 
matched with a patient treated with direct MT. We matched in a 1:1 ratio without replacement using a 
caliper width of 0.1. Standardized   difference 
<0.1 was considered to support the assumption of balance between the groups. We estimated the 
association of bridging therapy (vs direct MT) with outcome measures by calculating the unadjusted odds 
ratio (OR) with two-sided 95% confidence interval (CI) and the adjusted OR (aOR) with 95% CI after 
adjustment for pre-defined covariates (age; study period; NIHSS score; pre-stroke  mRS  score  ≤1;  
symptom  recognition  (or  awakening)-to-groin  puncture       time). 
  
ASPECT score entered only the adjustment models for 6-9-Point ASPECTS group. Statistical significance was 
established at two-tailed 0.05 level (P <0.05). 
Standard Protocol Approvals, Registrations, and Patient Consents 
Need for ethical approval or patient consent for participation in the IRETAS varied among participating 
hospitals. Ethical approval and informed consent were obtained when required. 
Data Availability Statement 



















Among 2556 acute ischemic stroke patients with ICA, M1-MCA, and M2-MCA occlusion and ASPECTS ≥6 
who were registered in the IRETAS cohort by 44 centers (Supplemental Table 2), 583 unknown onset stroke 
patients received endovascular procedures ≤6 hours of the symptom recognition or awakening in absence 
of absolute exclusion criteria for IVT. Flow diagram of patient inclusion and exclusion is provided in Figure 
1. 
The characteristics in the entire cohort (unwitnessed strokes, n=429; wake-up strokes, n=154) and in the 
10-Point ASPECTS (n=349) and 6-9-Point ASPECTS (n=134) groups are provided in Table 1. In the 10-Point 
ASPECTS group, 248 patients (unwitnessed strokes, n=214; wake-up strokes, n=34) received bridging 
therapy and 101 patients (unwitnessed strokes, n=60; wake-up strokes, n=41) received direct MT. In the 6-
9-Point ASPECTS group, 123 patients (unwitnessed strokes, n=109; wake-up strokes, n=14) received 
bridging therapy and 111 patients  (unwitnessed 
  
strokes, n=46; wake-up strokes, n=65) received direct MT. Data for execution (or not) of perfusion CT or 
MRI were collected in 346/583 patients. In the 10-Point ASPECTS group, perfusion CT or MRI was 
performed in 81 (70.4%) patients treated with bridging therapy and 47 (72.3%) patients treated with direct 
MT. In the 6-9-Point ASPECTS group, perfusion CT or MRI was performed in 69 (81.2%) patients treated 
with bridging therapy and 69 (85.2%) patients treated with direct MT. 
In the 10-Point ASPECTS group, diabetes mellitus (p=0.020), wake-up stroke (p<0.001), good collateral 
circulation (p=0.006) were more frequent in patients treated with direct MT. In the 6-9- Point ASPECTS 
group, patients treated with bridging therapy were more often enrolled during the 2016-2017 study period 
(p=0.045) and underwent general anesthesia (p=0.040), while antiplatelet use (p=0.040) and wake-up 
stroke (p<0.001) were more frequent in patients treated with direct MT; distribution of type of procedure 
was different between the groups (p=0.002). In the 10-Point ASPECTS group, rates of excellent (43.1% vs 
26.6%, p=0.006) and favorable functional outcome (54.8% vs 39.4%, p=0.015) were higher in patients 
treated with bridging therapy. Any ICH was reported in the 67 patients treated with bridging therapy (HI-1, 
n=32; HI- 2, n=11; PH-1, n=15; PH-2, n=7; SAH alone, n=2; SAH plus HI or PH, n=5;) and in 21 patients 
treated with direct-MT (HI-1, n=7; HI-2, n=4; PH-1, n=3; PH-2, n=4; SAH alone, n=3; SAH plus HI or PH, n=1). 
In the 6-9-Point ASPECTS group, no significant difference on functional and radiological outcome measures 
were found. Any ICH was reported in the 35 patients treated with bridging therapy (HI-1, n=9; HI-1, n=17; 
PH-1, n=5; PH-2, n=3; SAH alone, n=1; SAH plus HI or PH, n=3) and in 34 patients treated with direct-MT (HI-
1, n=15; HI-1, n=8; PH-1, n=7; PH-2, n=4). 
After the first model of propensity score matching, the characteristics of the patients treated with bridging 
and direct MT in the 10-Point-ASPECTS (n=73 vs n=73) and 6-9-Point ASPECTS (n=45 vs n=45) groups are 
provided in Supplemental Table 3. An absolute standardized difference (ASD) was <10% for all covariates. In 
the 10-Point ASPECTS group,  bridging therapy was associated with higher rates of excellent functional 
outcome (46.6% vs 28.8%; OR: 2.159, 95% CI: 1.089-4.279; aOR: 2.302, 95% CI: 1.010-5.244) and successful 
recanalization 
(83.6% vs 63%; OR: 2.984, 95% CI: 1.367-6.511; aOR: 3.028, 95% CI: 1.369-6.693) (Table   2). 
No significant association were found between bridging therapy and direct MT as regards rate of favorable   
functional   outcome   (54.8%   vs   41.1%),   death   (17.8%   vs   19.2%),    complete 
  
recanalization (17.8% vs 19.2%), any ICH (27.4% vs 21.9%), PH (8.2% vs 6.8%), and sICH (0 vs 1.4%) (Table 
2). In the 6-9-Point ASPECTS group, no significant associations were found between bridging therapy and 
direct MT as regards rates of excellent functional outcome (44.4% vs 31.1%), favorable functional outcome 
(60% vs 53.3%), death (15.6% vs 13.3%), complete 
recanalization (57.8% vs 55.6%), successful    recanalization (73.3% vs 76.5%), any ICH (33.3% 
vs 24.4%), PH (2.2% vs 6.7%), and sICH (0 vs 0) (Table 2). 
After the second model of propensity score matching, the characteristics of the patients treated with 
bridging and direct MT in the 10-Point-ASPECTS (n=47 vs n=47) and 6-9-Point ASPECTS (n=31 vs n=31) 
groups are provided in Supplemental Table 4. An absolute standardized difference (ASD) was <10% for all 
covariates. In the 10-Point ASPECTS group,  bridging therapy was associated with higher rates of excellent 
(44.7% vs 19.1%; OR: 3.410, 95% CI: 1.350-8.614; aOR: 5.816, 95% CI: 1.672-20.228) and favorable 
functional outcome (63.8% vs 
38.3%; OR: 2.843, 95% CI: 1.232-6.563; aOR: 4.094, 95% CI: 1.382-12.131), and successful 
recanalization (76.6% vs 57.4%; OR: 2.424, 95% CI: 1.009-5.897; aOR: 2.532, 95% CI:   1.022- 
6.275) (Table 3). No significant association were found between bridging therapy and direct MT as regards 
rate of death (12.8% vs 17%), complete recanalization (53.2% vs 38.3%), any ICH (19.1% vs 21.3%), PH (6.4% 
vs 4.3%), and sICH (2.1% vs 0) (Table 3). In the 6-9-Point ASPECTS group, no significant associations were 
found between bridging therapy and direct  MT as regards rates of excellent (41.9% vs 29%) and favorable 
functional outcome (64.5% vs 61.3%), death (12.9% vs 12.9%), complete (64.5% vs 51.6%) and successful 
recanalization 
(90.3% vs 77.4%), any ICH (25.8% vs 25.8%), PH (6.5% vs 9.7%), and sICH (0 vs 0) (Table 3). 
After the third model of propensity score matching, the characteristics of the patients treated with bridging 
and direct MT in the 10-Point-ASPECTS (n=34 vs n=34) and 6-9-Point ASPECTS (n=23 vs n=23) groups are 
provided in Supplemental Table 5. An absolute standardized difference (ASD) was <10% for all covariates. In 
the 10-Point ASPECTS group,  bridging therapy was associated with higher rates of excellent (44.1% vs 
20.6%; OR: 3.429, 95% CI: 1.176-9.994; aOR: 5.365, 95% CI: 1.57-24.888) and favorable functional outcome 
(61.8% vs 
35.3%;  OR:  2.962, 95% CI:  1.104-7.942;  aOR:  3.468, 95% CI:  1.023-13.013), and successful 
recanalization (85.3% vs 58.8%; OR: 4.060, 95% CI: 1.261-13.072; aOR: 3.879, 95% CI: 1.130- 
13.315) (Table 4). No significant association were found between bridging therapy and direct  MT as 
regards rate of death (14.7% vs 17.6%), complete recanalization (55.9% vs 38.2%), any 
  
ICH (20.6% vs 14.7%), PH (5.9% vs 2.9%), and sICH (3% vs 0) (Table 4). In the 6-9-Point ASPECTS group, no 
significant associations were found between bridging therapy and direct  MT as regards rates of excellent 
(43.5% vs 30.4%) and favorable functional outcome (60.9% vs 65.2%), death (13% vs 8.7%), complete 
(56.5% vs 52.2%) and successful recanalization  (91.3% 








Our study showed that bridging therapy vs direct MT was associated with better 3-month functional 
outcomes and a higher rate of successful recanalization in unknown onset stroke patients with ICA, M1-
MCA, or M2-MCA occlusion and 10-Point ASPECTS, who received endovascular treatment ≤6 hours of 
symptom recognition or awakening in absence of absolute exclusion criteria for IVT. Instead, radiological 
and functional outcomes were similar in the  group of patients with 6-9-Point ASPECTS. Bridging therapy 
did not increase the risk of intracerebral bleedings. 
The raw rates of recanalization are numerically lower in the group of patients with 10-Point ASPECT treated 
with direct MT as compared with the other three groups. We are unable to investigate whether the group 
of patients with 10-Point ASPECT treated direct MT could have more adverse conditions for recanalization 
such as difficult anatomical access, intracranial atherosclerotic stenosis, different thrombus etiology and 
composition, distal embolization or re- occlusion during the intervention, or different operator skills. 
Optimal treatment of stroke patients with unknown symptom onset remains uncertain. Only  some patients 
(11% and 5%, respectively) received bridging therapy in the endovascular treatment-arm of the DEFUSE-3 
(11%) and DAWN (5%) trials.4,5 In a different study, bridging therapy (n=19) vs direct IVT (n=21) was 
associated with 3-month favorable outcome in patients with LVO in the anterior circulation and DWI/FLAIR-
MRI mismatch.10 
In patients with known symptom onset, a recent meta-analysis showed that bridging therapy provides extra 
benefits to direct MT on radiological and functional outcomes as compared with direct MT in anterior LVO-
related strokes;11  however, direct MT was used more often in patients 
  
contraindicated to receive IVT. On the other side, the DIRECT-MT trial showed recently that direct MT was 
noninferior to bridging therapy with regard to the primary outcome (adjusted common OR for the 3-month 
mRS score) in Chinese patients who were eligible for IVT and IAT (<4.5 hours after symptom onset); 
however, direct MT was associated with lower percentages of patients with successful reperfusion after 
endovascular procedure.12 Why this improvement in reperfusion from the addition of IVT did not translate 
into clinical benefits is unclear.   However, 
the topic is currently being investigated in another ongoing trial (SWIFT DIRECT; NCT03192332) in European 
and North American Stroke Centers. 
The use of ASPECTS could facilitate an early initiation of IVT for a portion of patients with unknown onset 
stroke who are transported directly to the nearest non-endovascular capable center and then transferred 
to the nearest endovascular capable center for MT according to the drip and ship model. A previous study 
showed that ASPECTS correlated with CBV infarct core volume on CT-perfusion after 180 minutes from 
known symptom onset, and predicted final infarct volume in patients with complete recanalization and 3-
month functional outcome after 
endovascular treatment.13  In  addition,  a recent  study reported that the prevalence of   mismatch 
did not reduce over time (0-24 hours) among ASPECTS groups and higher ASPECTS was an independent 
predictor of clinical-core mismatch (i.e., clinical deficit out of proportion to infarct volume) in stroke 
patients with ICA or M1-MCA occlusion.14 Lack of systematically collected data of mismatch and infarct 
volume on perfusion imaging is the main limitation of our study, and this does not allow for a comparison 
with previous studies.13,14 
We are aware that our study has some limitations. First, the present study did not randomize patients by 
treatment, but it is based on a retrospective analysis of prospectively collected data. Second, the number of 
missing data for outcome measures and pre-defined variables might have influenced the final outcome. 
Third, reasons for the treatment were not recorded; it is likely that these choices were influenced by 
unmeasurable factors related to individual physician’s decision, which  might  have  influenced  our  key  
findings.  However,  patient  recruitment  in  our   study 
preceded  the  evidence  for  MT  in  unknown  onset  and  wake-up  stroke,3-6  and  the  choice of 
treatment could not be influenced by particular conditions which are listed in the absolute exclusion 
criteria for IVT. Fourth, lack of data for time last well known or sleep onset does not allow for a comparison 
with endovascular stroke trials4,5 to estimate the hypothetical onset of stroke.  Nevertheless,  the  
identification  of  possible  differences  between  bridging therapy and 
  
direct MT along an extended therapeutic window was not the aim of the present study. Fifth, imaging 
analysis to calculate ASPECTS was done locally and the CT images were not reviewed centrally. Finally, we 
did not use data of collateral circulation and type of procedure because of large amounts of missing values. 
CONCLUSIONS 
Bridging therapy within 6 hours of symptom recognition or awakening time was associated with better 3-
month functional outcomes and a higher rate of successful recanalization in unknown onset stroke patients 
with ICA, M1-MCA, or M2-MCA occlusion and 10-Point ASPECTS. However, our findings should be 
considered with caution, and a trial is needed to assess bridging therapy (IVT with Alteplase plus MT) vs 
direct MT in unknown onset stroke patients. 
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Table 1. Characteristics in the entire cohort and in the 10-Point-ASPECTS and 6-9-Points ASPECTS groups. 
  
ASPECTS 10 ASPECT 6-9 
 
 All patients Bridging  Direct  P therapy thrombectomy value
 Bridging therapy Direct thrombectomy P 
value 
 (n=583) (n=248) (n=101) (n=123) (n=111) 
Demographics      
Age (years), mean (SD) 70 (13) 70 (14) 72 (14) 0.372 71 (12) 69 (13) 0.238 
Male sex, n (%) 268 (46) 120 (48.4) 50 (49.5) 0.357 48 (39) 50 (45) 0.906 
Years      
2016-2017, n (%) 346 (59.3) 147 (59.3) 58 (57.4) 0.811 82 (66.7) 59 (53.2)
 0.045 
Medical history      
Hypertension, n (%) 334 (66.4) [80] 138 (63.6) [31] 49 (65.3) [26] 0.889 80 (71.4) [11] 67 (67.7) 
[12] 0.653 
Diabetes mellitus, n (%) 69 (13.7) [80] 24 (11.1) [31] 17 (22.7) [26] 0.020 14 (12.5) [11] 14 (14.1) 
[12] 0.839 
Previous stroke/TIA, n (%) 25 (5) [80] 8 (3.7) [31] 5 (6.7) [26] 0.330 5 (4.5) [11] 7 
(7.1) [12] 0.554 
Atrial fibrillation, n (%) 128 (25.4) [80] 57 (26.3) [31] 27 (36) [26] 0.138 19 (17) [11] 25 (25.3) 
[12] 0.174 
Antiplatelet, n (%) 205 (35.2) 88 (35.5) 36 (35.6) 1.000 35 (28.5) 46 (41.4)
 0.040 
Anticoagulant oral with INR ≤1.7, n (%) 23 (3.9) 7 (2.8) 5 (5) 0.339 5 (4.1) 6 (5.4) 0.760 
Baseline data      
Pre-stroke mRS score ≤1, n (%) 458 (90.5) [77] 200 (90.9) [28] 77 (89.5) [15] 0.671 94 (94) [23] 87 
(87) [11] 0.146 
NIHSS score, median (IQR) 18 (13-21) [7] 17 (12-20) 16 (12-20) [4] 0.656 18 (14-21) [2] 19 
(15-23) [1] 0.100 
Wake-up stroke, n (%) 154 (26.4) 34 (13.7) 41 (40.6) <0.001 14 (11.4) 65 (58.6)
 <0.001 
ASPECT score     0.605 
6, n (%) 36 (6.2) - - 17 (13.8) 19 (17.1)  
7, n (%) 45 (7.7) - - 21 (17.1) 24 (21.6)  
8, n (%) 71 (12.2) - - 41 (33.3) 30 (27)  
9, n (%) 82 (14.1) - - 44 (35.8) 38 (34.2)  
Occlusion site  0.478   0.302 
Intra-cranial ICA, n (%) 68 (11.7) 24 (9.7) 14 (13.9) 18 (14.6) 12 (10.8)  
M1-segment MCA, n (%) 409 (70.2) 175 (70.6) 66 (65.3) 83 (67.5) 85 (76.6)
  
M2-segment MCA, n (%) 106 (18.2) 49 (19.8) 21 (20.8) 22 (17.9) 14 (12.6)
  
Good collateral circulation, n (%) 240 (65.2) [215] 95 (56.2) [79] 37 (78.7) [54] 0.006 64 
(70.3) [32] 44 (72.1) [50] 0.857 
Execution of perfusion CT or MRI, n (%) 266 (76.9) [237] 81 (70.4) [133] 47 (72.3) [36] 0.865 69 
(81.2) [38] 69 (85.2) [30] 0.539 
General anesthesia, n (%) 238 (44.8) [52] 86 (37.7) [20] 31 (36) [15] 0.896 72 (62.6) [8] 49 
(48) [9] 0.040 
Symptom recognition (or awakening)-to- 240 (190-286) 240 (194-280) 241 (180-297) 0.850 240 
(200-290) 233 (169-300) 0.309 
groin puncture time (min), median (IQR)      
Type of procedure  0.750   0.002 
Aspiration alone, n (%) 212 (47) [132] 82 (43.4) [59] 30 (38.5) [23] 62 (63.9) [26] 38 (43.7) [24]  
Stent retriever alone, n (%) 172 (38.1) [132] 79 (41.8) [59] 36 (46.2) [23] 19 (19.6) [26] 38 
(43.7) [24]  
Combination of aspiration and stent 67 (14.9) [132] 28 (14.8) [59] 12 (15.4) [23] 16 (16.5) [26] 11 
(12.6) [24]  
retriever, n (%)      
Procedure time (min), median (IQR) 65 (44-93) [4] 68 (45-100) [1] 77 (41-100) [1] 0.995 58 (35-90) 
[2] 64 (45-84) 0.183 
Functional outcome measures      
mRS score 0-1, n (%) 207 (37.4) [30] 103 (43.1) [9] 25 (26.6) [7] 0.006 44 (37.6) [6] 35 (34) [8]
 0.673 
mRS score 0-2, n (%) 286 (51.7) [30] 131 (54.8) [9] 37 (39.4) [7] 0.015 63 (53.8) [6] 55 (53.4) [8]
 1.000 
  
Death, n (%) 81 (14.6) [30] 36 (15.1) [9] 18 (19.1) [7] 0.409 16 (13.7) [6] 11 (10.7) [8]
 0.542 
Radiological outcome measures        
TICI 3, n (%) 325 (56.2) [5] 142 (57.5) [1] 48 (48) [1] 0.122 71 (57.7) 64 (59.3) [3]
 0.894 
TICI 2b/3, n (%) 435 (75.3) [5] 185 (74.9) [1] 67 (67) [1] 0.145 97 (78.9) 86 (79.6) [3]
 1.000 
Any ICH, n (%) 157 (27.7) [17] 67 (27.5) [4] 21 (21.9) [5] 0.336 35 (29.4) [4] 34 (31.8) [4]
 0.773 
PH, n (%) 48 (8.5) [17] 22 (9) [4] 7 (7.3) [5] 0.393 8 (6.7) [4] 11 (10.3) [4]
 0.235 
sICH, n (%) 11 (2) [42] 6 (2.5) [12] 1 (1.1) [6] 0.335 2 (1.8) [14] 2 (2) [10]
 0.660 
 









Table 2. Associations of bridging therapy versus direct thrombectomy with outcome measures after the 
first model of propensity score matching. 
  ASPECTS 10  ASPECTS 10   ASPECTS 6-9  ASPECTS 6-9
  
 N (%) Unadjusted OR P Adjusted OR P N (%) Unadjusted OR P Adjusted OR
 P 
  (95% CI) value (95% CI) value  (95% CI) value (95% CI)
 value 
mRS score 0-1           
Bridging 34 (46.6) 2.159 (1.089-4.279) 0.028 2.302 (1.010-5.244) 0.047 20 (44.4)
 1.771 (0.748-4.197) 0.194 1.534 (0.554-4.249) 0.411 
Direct MT 21 (28.8) 1.000  1.000  14 (31.1)     
mRS score 0-2           
Bridging 40 (54.8) 1.737 (0.902-3.347) 0.099 1.795 (0.793-4.062) 0.161 27 (60)
 1.312 (0.569-3.028) 0.524 1.012 (0.375-2.736) 0.981 
Direct MT 30 (41.1) 1.000  1.000  24 (53.3)     
Death           
Bridging 13 (17.8) 0.913 (0.396-2.107) 0.831 0.838 (0.338-2.081) 0.704 7 (15.6)
 1.197 (0.369-3.890) 0.764 1.341 (0.371-4.852) 0.655 
Direct MT 14 (19.2) 1.000  1.000  6 (13.3)     
TICI 3           
Bridging 42 (57.5) 1.642 (0.854-3.159) 0.137 1.690 (0.862-3.314) 0.126 26 (57.8)
 1.095 (0.475-2.521) 0.832 0.971 (0.406-2.321) 0.947 
Direct MT 33 (45.2) 1.000  1.000  25 (55.6)     
TICI 2b/3           
Bridging 61 (83.6) 2.984 (1.367-6.511) 0.006 3.028 (1.369-6.693) 0.006 33 (73.3)
 0.890 (0.345-2.296) 0.809 0.786 (0.287-2.152) 0.639 
Direct MT 46 (63) 1.000  1.000  34 (76.5)     
Any ICH          
Bridging 20 (27.4) 1.344 (0.631-2.864) 0.443 1.266 (0.574-2.795) 0.559 15 (33.3)
 1.545 (0.616-3.878) 0.354 2.252 (0.769-6.599) 0.139 
Direct MT 16 (21.9) 1.000  1.000  11 (24.4)     
PH           
Bridging 6 (8.2) 1.218 (0.355-4.183) 0.754 1.146 (0.324-4.058) 0.832 1 (2.2) 0.318 
(0.032-3.181) 0.330 0.028 (0.005-2.905) 0.131 
Direct MT 5 (6.8) 1.000  1.000  3 (6.7)     
sICH           
Bridging 0 - NA - NA 0 - NA - NA 








ORs were adjusted for pre-defined variables (age; study period; pre-stroke mRS score ≤1; NIHSS score; 
symptom (or awakening)- recognition-to-groin puncture time). ASPECT score entered the adjustment 








Table 3. Associations of bridging therapy versus direct thrombectomy with outcome measures after the 
second model of propensity score matching. 
  ASPECTS 10  ASPECTS 10   ASPECTS 6-9  ASPECTS 6-9
  
 N (%) Unadjusted OR P Adjusted OR P N (%) Unadjusted OR P Adjusted OR
 P 
  (95% CI) value (95% CI) value  (95% CI) value (95% CI)
 value 
mRS score 0-1           
Bridging 21 (44.7) 3.410 (1.350-8.614) 0.009 5.816 (1.672-20.228) 0.006 13 (41.9)
 1.765 (0.615-5.064) 0.290 1.840 (0.603-5.614) 0.284 
Direct MT 9 (19.1) 1.000  1.000  9 (29)     
mRS score 0-2           
Bridging 30 (63.8) 2.843 (1.232-6.563) 0.014 4.094 (1.382-12.131) 0.011 20 (64.5)
 1.148 (0.409-3.221) 0.793 0.933 (0.291-2.991) 0.907 
Direct MT 18 (38.3) 1.000  1.000  19 (61.3)     
Death           
Bridging 6 (12.8) 0.713 (0.227-2.243) 0.563 0.709 (0.195-2.571) 0.601 4 (12.9) 1.000 
(0.226-4.415) 1.000 1.071 (0.228-5.030) 0.931 
Direct MT 8 (17) 1.000  1.000  4 (12.9)     
TICI 3           
Bridging 25 (53.2) 1.831 (0.805-4.161) 0.149 1.944 (0.836-4.521) 0.123 20 (64.5)
 1.705 (0.616-4.720) 0.305 1.836 (0.608-5.546) 0.281 
Direct MT 18 (38.3) 1.000  1.000  16 (51.6)     
TICI 2b/3           
Bridging 36 (76.6) 2.424 (1.009-5.897) 0.049 2.532 (1.022-6.275) 0.045 28 (90.3)
 2.722 (0.633-11.701) 0.178 2.971 (0.584-15.113) 0.189 
Direct MT 27 (57.4) 1.000  1.000  24 (77.4)     
Any ICH          
Bridging 9 (19.1) 0.876 (0.320-2.401) 0.797 0.876 (0.307-2.502) 0.805 8 (25.8) 1.000 
(0.321-3.120) 1.000 1.089 (0.318-3.734) 0.892 
Direct MT 10 (21.3) 1.000  1.000  8 (25.8)     
PH           
Bridging 3 (6.4) 1.534 (0.244-9.629) 0.648 1.509 (0.204-11.183) 0.687 2 (6.5) 0.644 
(0.100-4.147) 0.643 1.725 (0.080-37.046) 0.728 
Direct MT 2 (4.3) 1.000  1.000  3 (9.7)     
sICH           
Bridging 1 (2.1) - NA - NA 0 - NA - NA 








ORs were adjusted for pre-defined variables (age; study period; pre-stroke mRS score ≤1; NIHSS score; 
symptom recognition (or awakening)-to-groin puncture time). ASPECT score entered the adjustment model 








Table 4. Associations of bridging therapy versus direct thrombectomy with outcome measures after the 
third model of propensity  score matching. 
  ASPECTS 10  ASPECTS 10   ASPECTS 6-9  ASPECTS 6-9
  
 N (%) Unadjusted OR P Adjusted OR P N (%) Unadjusted OR P Adjusted OR
 P 
  (95% CI) value (95% CI) value  (95% CI) value (95% CI)
 value 
mRS score 0-1           
Bridging 21 (47.1) 3.429 (1.176-9.994) 0.024 5.365 (1.157-24.888) 0.032 10 (43.5)
 1.758 (0.523-5.907) 0.361 2.055 (0.497-8.489) 0.320 
Direct MT 9 (20.6) 1.000  1.000  7 (30.4)     
mRS score 0-2           
Bridging 30 (61.8) 2.962 (1.104-7.942) 0.031 3.648 (1.023-13.013) 0.046 14 (60.9)
 0.830 (0.250-2.752) 0.760 0.625 (0.138-2.837) 0.543 
Direct MT 18 (35.3) 1.000  1.000  15 (65.2)     
Death           
Bridging 5 (14.7) 0.805 (0.220-2.939) 0.742 0.923 (0.205-4.158) 0.917 3 (13) 1.575 
(0.238-10.437) 0.638 1.500 (0.187-12.064) 0.703 
Direct MT 6 (17.6) 1.000  1.000  2 (8.7)     
TICI 3           
Bridging 25 (55.9) 2.046 (0.777-5.386) 0.147 2.130 (0.750-6.051) 0.156 13 (56.5)
 1.192 (0.373-3.807) 0.767 1.243 (0.340-4.539) 0.742 
Direct MT 18 (38.2) 1.000  1.000  12 (52.2)     
TICI 2b/3           
Bridging 36 (85.3) 4.060 (1.261-13.072) 0.019 3.879 (1.130-13.315) 0.031 21 (91.3)
 2.211 (0.363-13.470) 0.390 3.203 (0.309-33.224) 0.329 
Direct MT 27 (58.8) 1.000  1.000  19 (82.6)     
Any ICH          
Bridging 7 (20.6) 1.504 (0.426-5.310) 0.526 1.482 (0.396-5.556) 0.559 6 (26.1) 0.807 
(0.223-2.920) 0.744 0.749 (0.180-3.104) 0.690 
Direct MT 5 (14.7) 1.000  1.000  7 (30.4)     
PH           
Bridging 2 (5.9) 2.062 (0.178-23.882) 0.562 2.709 (0.199-36.834) 0.454 1 (4.3) 0.303 
(0.029-3.155) 0.318 1.265 (0.043-36.978) 0.891 
Direct MT 1 (2.9) 1.000  1.000  3 (13)     
sICH           
Bridging 1 (3) - NA - NA 0 - NA - NA 








ORs were adjusted for pre-defined variables (age; study period; pre-stroke mRS score ≤1; NIHSS score; 
symptom recognition (or awakening)-to-groin puncture time). ASPECT score entered the adjustment model 
for 6-9-Points ASPECTS groups. 
  
 
 
 
 
  
 
ene_14529_f1.jpg 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
